TG Therapeutics (TGTX) Soars 7.5%: Is Further Upside Left in the Stock?
TG Therapeutics (TGTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Zacks
More News
TGTX Rises on Positive Phase I Data for Subcutaneous Briumvi in MG
TG Therapeutics gains after positive phase I data for subcutaneous Briumvi in myasthenia gravis or MG, while a phase II study in MG gets underway.
Zacks
TGTX Stock Jumps 5% On Positive Early Data For At-Home BRIUMVI In Muscle Disease
TGTX’s early-stage study showed the injectable form of BRIUMVI delivered quick and meaningful symptom relief in most myasthenia gravis patients.
Stocktwits
Why Is TG Therapeutics Stock Gaining Tuesday?
TGTX stock rises on positive Phase 1 data for subcutaneous BRIUMVI in myasthenia gravis. See what's next for TG Therapeutics.read more...
Benzinga
Why Is TG Therapeutics (TGTX) Down 5.7% Since Last Earnings Report?
TG Therapeutics (TGTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
TGTX Stock Up on Positive Phase I Data for Subcutaneous Briumvi
TG Therapeutics jumps 9.5% after phase I data show that subcutaneous Briumvi achieved over 60% bioavailability, sustained drug exposure, and was well tolerated.
Zacks
TG Therapeutics Stock Surges After Drug Trial Update
Shares of TG Therapeutics Inc (NASDAQ: TGTX) are climbing Wednesday after early-stage clinical trial data for new BRIUMVI MS formulation.read more...
Benzinga
TGTX Stock Applies Brakes On 5-Session Losing Streak – Retail Eyes ‘Multi-Billion’ Sales As At-Home Multiple Sclerosis Treatment Gets Boost
The company announced positive Phase 1 results for a subcutaneous formulation of Briumvi, evaluating it against the currently approved IV formulation.
Stocktwits
TGTX's Single-Dose Briumvi Hits Bioequivalence Goal in MS Study
TG Therapeutics announces that Briumvi's late-stage ENHANCE study met its goal, supporting a potential single-infusion regimen for relapsing MS patients.
Zacks
TGTX Stock Rises 29% in 3 Months: Here's What You Should Know
TG Therapeutics gains on strong Briumvi sales growth, higher 2026 revenue guidance and advancing late-stage studies in RMS.